apremilast among patients with moderate to severe plaque psoriasis by metabolic syndrome status. Poster presented at: ISPOR 2019
home / authors / apremilast-among-patients-with-moderate-to-severe-plaque-psoriasis-by-metabolic-syndrome-status-poster-presented-at-ispor-2019
Articles
September 27th 2019
Feldman SR, Zhang J, Martinez D, et al. Treatment patterns of biologics apremilast among patients with moderate to severe plaque psoriasis by metabolic syndrome status. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-1479/92502.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 21st 2024 | Updated: November 23rd 2024
Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment
